Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/13267
Title: | Epigenetic-based treatment as a potential strategy to treat Friedreich’s ataxia |
Authors: | Grech, Alfred Baldacchino, Alexandra |
Keywords: | Friedreich's ataxia Epigenetics Nervous system -- Diseases -- Treatment Nervous system -- Degeneration |
Issue Date: | 2013 |
Publisher: | Medical Portals Ltd. |
Citation: | Grech, A. & Baldacchino, A. (2013). Epigenetic-based treatment as a potential strategy to treat Friedreich’s ataxia. The Synapse, (5), 10-12 |
Abstract: | Friedreich’s ataxia (FRDA) is an autosomal recessive neurodegenerative disorder. It is the most common inherited ataxia in Europe. The neurodegeneration is progressive and normally, within 15-20 years, the patient becomes wheel-chair bound, and ultimately, is totally incapacitated. Affected individuals normally succumb from heart complications. Frataxin (FXN) is a mitochondrial protein that is deficient in FRDA. The deficiency is caused by a mutation within the first intron of the FXN gene which codes for frataxin. Epigenetic mechanisms are responsible in FRDA and epigenetic-based treatment is a potential new strategy to treat FRDA. |
URI: | https://www.um.edu.mt/library/oar//handle/123456789/13267 |
Appears in Collections: | The Synapse, Issue 5 The Synapse, Issue 5 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Epigenetic-based treatment.pdf | 949.46 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.